Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Zentalis Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Zentalis Pharmaceuticals, Inc.’s stock price such as:

• Zentalis Pharmaceuticals, Inc.’s current stock price and volume
• Why Zentalis Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for ZNTL from analysts
• ZNTL’s stock price momentum as measured by its relative strength

About Zentalis Pharmaceuticals, Inc. (ZNTL)

Before we jump into Zentalis Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.

Want to learn more about Zentalis Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Zentalis Pharmaceuticals, Inc..

Zentalis Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Zentalis Pharmaceuticals, Inc.’s stock price was $4.740.

Zentalis Pharmaceuticals, Inc. is down 3.66% from its previous closing price of $4.920.

During the last market session, Zentalis Pharmaceuticals, Inc.’s stock traded between $4.660 and $4.990. Currently, there are approximately 70.26 million shares outstanding for Zentalis Pharmaceuticals, Inc..

Zentalis Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Zentalis Pharmaceuticals, Inc. Stock Price History

Zentalis Pharmaceuticals, Inc.’s (ZNTL) price is currently down 2.27% so far this month.

During the month of July, Zentalis Pharmaceuticals, Inc.’s stock price has reached a high of $5.580 and a low of $4.131.

Over the last year, Zentalis Pharmaceuticals, Inc. has hit prices as high as $6.950 and as low as $1.212. Year to date, Zentalis Pharmaceuticals, Inc.’s stock is up 251.11%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Zentalis Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Zentalis Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Zentalis Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Zentalis Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Zentalis Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Zentalis Pharmaceuticals, Inc. (ZNTL) by visiting AAII Stock Evaluator.

Relative Price Strength of Zentalis Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Zentalis Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 29.00%, which translates to a Momentum Score of 96 and is considered to be Very Strong.

Want to learn more about how Zentalis Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Zentalis Pharmaceuticals, Inc. Stock Price: Bottom Line

As of July 31, 2026, Zentalis Pharmaceuticals, Inc.’s stock price is $4.740, which is down 3.66% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Zentalis Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.